Israel - English - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii - powder and solvent for solution for injection - factor viii 500 iu/vial - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)this preparation does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand's disease.

Israel - English - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 1000 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease

Ireland - English - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 250 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 2400 iu; factor viii, quantity: 1000 iu - injection, powder for - excipient ingredients: sodium chloride; sodium citrate dihydrate; calcium chloride dihydrate; albumin; sucrose; trometamol - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; trometamol; sodium chloride; albumin; sodium citrate dihydrate; calcium chloride dihydrate - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, powder for - excipient ingredients: sodium citrate dihydrate; trometamol; calcium chloride dihydrate; albumin; sucrose; sodium chloride - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.